Ascendis Pharma A/S
NASDAQ:ASND

Watchlist Manager
Ascendis Pharma A/S Logo
Ascendis Pharma A/S
NASDAQ:ASND
Watchlist
Price: 129.81 USD 5.85% Market Closed
Market Cap: 7.4B USD
Have any thoughts about
Ascendis Pharma A/S?
Write Note

Operating Margin
Ascendis Pharma A/S

-111.3%
Current
-2 863%
Average
-7.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-111.3%
=
Operating Profit
-353.4m
/
Revenue
317.6m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
DK
Ascendis Pharma A/S
NASDAQ:ASND
7.6B USD
-111%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
312.7B USD
28%
US
Amgen Inc
NASDAQ:AMGN
158.3B USD
19%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD
40%
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
133.6B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
34.5B EUR
-22%
Country DK
Market Cap 7.6B USD
Operating Margin
-111%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 312.7B USD
Operating Margin
28%
Country US
Market Cap 158.3B USD
Operating Margin
19%
Country US
Market Cap 115.9B USD
Operating Margin
40%
Country US
Market Cap 112.4B USD
Operating Margin
38%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 133.6B AUD
Operating Margin
26%
Country US
Market Cap 82.6B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 34.5B EUR
Operating Margin
-22%
No Stocks Found

Ascendis Pharma A/S
Glance View

Market Cap
7.6B USD
Industry
Biotechnology

Ascendis Pharma A/S is a biopharmaceutical company that is dedicated to transforming the lives of patients through innovative therapies, particularly in the areas of endocrine diseases, oncology, and rare diseases. Founded in 2006 and based in Copenhagen, Denmark, Ascendis has developed a unique platform called TransCon technology, which enables the creation of new medicines that enhance the therapeutic potential of existing drugs. This innovative approach is designed to improve dosing regimens and reduce side effects, positioning Ascendis as a game-changer in the pharmaceutical landscape. With a robust pipeline, including its lead product candidate, TransCon Growth Hormone, currently in late-stage development for growth hormone deficiency, the company is strategically positioned to capture significant market potential. For investors, Ascendis Pharma represents an enticing opportunity within the biopharmaceutical sector, particularly as it navigates pivotal clinical trials and potential regulatory approvals. The company boasts a strong financial foundation, having secured substantial funding from partnerships and public offerings to support its clinical programs. With a growing emphasis on long-term value creation derived from its innovative approach to drug development, Ascendis aims to become a key player in addressing unmet medical needs. As it advances its pipeline and explores partnerships with larger pharmaceutical companies, beckoning the prospects of lucrative collaborations, investors have a chance to become involved in the journey of a company poised at the intersection of science and patient care.

ASND Intrinsic Value
118.13 USD
Overvaluation 9%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-111.3%
=
Operating Profit
-353.4m
/
Revenue
317.6m
What is the Operating Margin of Ascendis Pharma A/S?

Based on Ascendis Pharma A/S's most recent financial statements, the company has Operating Margin of -111.3%.